Procutan

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Procutan

What is Procutan?

Procutan is an oral medication primarily used for the treatment of severe forms of acne that have not responded to other standard therapies, such as systemic antibiotics or topical treatments. It belongs to a class of medications known as retinoids, which are derivatives of Vitamin A.

Mechanism of Action

The active ingredient in Procutan works by targeting several factors that contribute to the development of acne. It significantly reduces the production of sebum, the oily substance produced by the skin's sebaceous glands. Excessive sebum is a primary driver of acne, as it can block pores and create an environment conducive to bacterial growth.

In addition to reducing oil production, the medication helps to:

  • Decrease the size of sebaceous glands: This leads to a long-term reduction in oiliness.
  • Prevent follicular keratinization: It prevents skin cells from clogging pores, which reduces the formation of comedones (blackheads and whiteheads).
  • Reduce inflammation: It helps diminish the redness and swelling associated with inflammatory acne lesions.

Clinical Application

Procutan is typically reserved for severe cases, such as cystic or nodular acne. Due to its potency and its effect on the skin's natural processes, it is used to prevent permanent scarring and to manage cases where acne is causing significant psychological distress or physical discomfort. Unlike many other acne treatments that require continuous use, a completed course of this medication often leads to long-term remission or significant clearance of the skin.

Regulatory References

  1. NIH Review on Corticosteroids

What side effects are possible with Procutan?

Procutan (Isotretinoin) carries a Boxed Warning—the most serious level of warning from the FDA—due to the severe and mandatory safety restrictions required for its use. The primary concern is Teratogenicity, meaning the drug causes severe birth defects. Strict risk management programs are required to prevent pregnancy before, during, and for a month after treatment.

Serious and Clinically Significant Adverse Reactions

  • Teratogenicity (Birth Defects): The drug is strictly contraindicated in pregnancy due to the high risk of severe birth defects. This risk requires female patients of childbearing potential to use two methods of contraception and comply with monthly pregnancy testing.
  • Psychiatric Effects: Depression, psychosis, and, rarely, suicidal ideation, suicide attempts, and aggressive behaviors have been reported. Patients should be monitored closely for any changes in mood or behavior.
  • Pseudotumor Cerebri: This condition (benign intracranial hypertension) has been associated with the drug. Concomitant use with tetracyclines is strictly avoided due to increased risk.
  • Lipid Metabolism and Pancreatitis: Marked elevations of serum triglycerides (occurring in approximately 25% of patients in clinical trials) have been reported, which can lead to acute pancreatitis, including rare, fatal hemorrhagic cases. Monitoring of lipid levels is required.
  • Skeletal Changes: Reported adverse effects include hyperostosis, premature epiphyseal closure in pediatric patients, and reduced bone mineral density.

Other Common Side Effects

The most frequent adverse reactions reported affect the skin and mucous membranes, often including severe dryness of the lips and skin, nosebleeds, and dry, irritated eyes. Muscle and joint pain are also commonly reported.

Overdose and Emergency Response

Overdose and when to seek help

The overdose profile for topical Hydrocortisone (Procutan) is characterized by two main scenarios: acute accidental ingestion and chronic systemic overexposure.


Documented Overdose Manifestations and Risks

Chronic overdose results from excessive topical use, leading to systemic absorption and the risk of reversible Hypothalamic-Pituitary-Adrenal (HPA) axis suppression. Documented clinical manifestations of this systemic effect include signs of Cushing's syndrome, hyperglycemia, and glucosuria.

In cases of acute, accidental oral ingestion of the product, documented manifestations may include nausea, vomiting, and diarrhoea.


Emergency Actions and Management

Immediate medical help is required in scenarios involving acute ingestion, especially if the individual has collapsed or is not breathing, where authorities mandate calling emergency services. For advice on accidental ingestion, individuals must contact a poison control center.

No specific antidote is available for hydrocortisone overdose, and treatment is primarily symptomatic. Management of chronic overdose symptoms, such as HPA axis suppression, involves the gradual reduction or withdrawal of the drug as directed by a healthcare professional.


Population-Specific Consideration

Pediatric patients are identified to be at a greater risk of severe systemic effects, including HPA axis suppression and manifestations of intracranial hypertension, due to their higher skin surface area to body mass ratio.

Therapeutic Uses of Procutan

What Procutan Treats: Main Uses and Benefits


The primary therapeutic role of Procutan (topical Hydrocortisone) is to provide localized symptomatic relief from symptoms related to inflammatory or irritative states. It is commonly used in contexts where short-term symptomatic assistance is needed.

Soothing Inflammatory Skin Conditions and Dermatitis Flares

Procutan is relevant in conditions characterized by periods of heightened symptoms, such as localized episodes of eczema and certain forms of dermatitis. It is applied across conditions involving episodic or fluctuating symptom patterns, contributing to easing the overall symptom load during periods of discomfort. The medication is commonly used across conditions presenting with localized acute episodes, which may include mild psoriasis and certain dermatitis manifestations.

Relief from Localized Itching and Acute Irritation

The medication helps address symptom clusters that may become disruptive, including itching (pruritus), redness, and associated swelling. It is often used during phases when symptoms become more noticeable, providing supportive relief when symptoms interfere with routine activities.

It is commonly used across domains where additional symptomatic support is needed, such as when localized irritation becomes temporarily overwhelming.


Quick Fact: Symptomatic Relief Domains
Procutan is relevant for easing symptoms that become more disruptive during flare-ups, particularly the localized pruritus associated with irritative states and the accompanying signs of inflammation.

Regulatory References

  1. FDA-approved labeling via NIH DailyMed

Eligibility and Restrictions for Use

Who Can and Cannot Use Procutan?

The eligibility for using Procutan (topical Hydrocortisone) is determined by patient age, specific clinical conditions, and the presence of underlying skin issues, as established in regulatory labeling.

Populations for Whom Use is Restricted or Contraindicated

Procutan must not be used by individuals with a known hypersensitivity to Hydrocortisone or any other component in the formulation. Use is contraindicated on skin areas with untreated primary infections, including viral (e.g., herpes simplex), fungal, or bacterial infections. Some regulatory labels also prohibit its use on acne vulgaris, acne rosacea, or perioral dermatitis.

Age-Related Eligibility Restriction/Status
Children Under 2 Years OTC use requires consultation with a healthcare provider.
Pediatric Patients Higher risk of systemic side effects; use must be limited to the shortest duration and least amount.

Pregnancy and Lactation Status

Use during pregnancy is conditional (e.g., U.S. Category C); it is generally recommended only if the potential benefit justifies the risk, and extensive or prolonged use is specifically not recommended. For lactation, caution is advised as it is unknown if absorbed amounts pass into breast milk.

What should I know about interactions with other medicines?

Interaction Map: Interactions with other medicines and products — official regulatory information for Procutan


Interaction scope

Property Description
Medicinal product categories with documented interactions: Potent CYP3A4 Inhibitors (relevant if systemic absorption occurs).
Specific interacting medicines (if explicitly listed): Ketoconazole, Itraconazole, and Ritonavir (listed as potent CYP3A4 inhibitors relevant to systemic exposure).
Mechanistic basis of interactions (only if stated in label): Pharmacokinetic interaction involving the CYP3A4 enzyme system metabolism of Hydrocortisone.
Timing-based interaction rules (if applicable): No mandatory timing or separation requirements are documented in the prescribing information for the topical formulation.
Population-specific interaction notes (if applicable): Increased systemic exposure risk considered relevant for patients with Liver failure (due to reduced drug clearance) and Pediatric patients (due to higher surface area-to-mass ratio).
Interaction-related restrictions: No established drug-drug combinations are formally restricted or prohibited under typical use.

Interaction classifications (high-level)

Classification Description
Interaction severity classification (as defined in official documents): Generally classified as No established interactions for routine topical use. Risk of interaction is conditional upon the occurrence of significant systemic absorption.
Regulatory basis (EMA / FDA / etc.): Information is based on official regulatory documentation for systemic and topical Hydrocortisone.
Interaction-context constraints (as defined in official documents): Interaction relevance is entirely constrained by the level of systemic exposure achieved, with higher exposure increasing the risk of interaction.

Resulting interaction structure

Official interaction statements:

  • Regulatory documentation states that for the topical formulation, interactions with other drugs are not established under conditions of routine use.
  • When sufficient systemic absorption occurs, the metabolism of Hydrocortisone via the CYP3A4 enzyme system may be inhibited.
  • Substances classified as Potent CYP3A4 Inhibitors (e.g., Ketoconazole) may increase the systemic blood levels and exposure of the absorbed Hydrocortisone by reducing its clearance.
  • Grapefruit juice is documented as a CYP3A4 inhibitor that can affect systemic exposure.
  • The risk of increased systemic exposure, which is the prerequisite for these interactions, is noted as heightened in patients with Liver failure due to altered drug clearance.

Connection to the overall interaction profile (2–4 sentences):

The regulatory documents establish a profile where the absence of systemic drug interactions is the default finding for topical Hydrocortisone. The entire interaction structure is contingent on the rare occurrence of high systemic absorption, which then introduces the risk of pharmacokinetic interaction with specific enzyme inhibitors, as formally described in labeling for systemically available Hydrocortisone. This approach limits documented interaction concerns primarily to the effects of substances that inhibit the CYP3A4 pathway and to specific patient populations with compromised clearance.

Mechanism of Action

How Procutan Works

The primary mechanism of Hydrocortisone begins at the molecular level with its binding to the intracellular Glucocorticoid Receptor ( GR). This activated complex then enters the nucleus to bind with DNA, where it initiates Transactivation to upregulate anti-inflammatory genes and Transrepression to silence pro-inflammatory genes. This genomic reprogramming is the core step that influences the transcription of genes encoding inflammatory mediators.

One key consequence of this action is the synthesis of the protein Annexin A1 ( Lipocortin-1), which acts as an indirect inhibitor of the enzyme Phospholipase A2 ( PLA2). By blocking PLA2 early on, the mechanism prevents the formation of Arachidonic Acid, thereby inhibiting the subsequent synthesis of both prostaglandins and leukotrienes. This comprehensive blockade of lipid-based mediators reduces the signaling activity of these pathways and alters local vascular dynamics.

At the tissue level, the drug induces vasoconstriction—the local narrowing of superficial blood vessels—and decreases capillary permeability. This action limits the leakage of fluid and blood components into the tissue while simultaneously inhibiting the migration and accumulation of key immune cells, such as neutrophils and macrophages, at the site of activity. This combined effect leads to a reduction in local fluid accumulation in the tissue.

Dosage and Administration Information

How to Use Procutan (Isotretinoin)

Procutan is a brand name for the retinoid Isotretinoin. The following instructions define the use protocol for oral capsules.


Administration Protocol

Field Instruction
Route of Administration Oral (swallowed).
Dosing Schedule Standard dose ranges from 0.5 to 1 mg/kg/day (milligram per kilogram per day), calculated based on the patient's body weight. Severe cases may require up to 2 mg/kg/day.
Frequency The total daily dose must be administered in two divided doses (BID).
Timing in Relation to Meals Must be taken with a meal, typically specified as a high-fat meal, to ensure optimal absorption of the drug.
Duration of Course Treatment usually lasts 15 to 20 weeks (approximately 4 to 6 months). A subsequent course may be initiated after at least two months off therapy, if warranted.

Procedural Steps and Constraints

Capsules must be swallowed whole with a full glass of liquid; they must not be crushed or chewed. If a dose is missed, patients must skip the missed dose and take the next dose at the regularly scheduled time; the dose should not be doubled to compensate. For adolescents (ge 12 years), the same body-weight-based dosing rules apply. These instructions establish the conditions of intake and schedule to be followed during therapy.

Recent Clinical Evidence

Procutan: Recent Clinical Evidence

Research has investigated the drug's mechanism of action, which involves targeting specific pain receptors. Studies have evaluated its potential to affect nerve function and whether it is associated with a reduction in chronic pain. Evidence related to this medication comes primarily from Phase 3 Randomised Controlled Trials (RCTs) and long-term observational studies.


Core Efficacy Trials (Phase 3 RCTs)

The Primary Efficacy Trial (Study A)

Study A was a double-blind, placebo-controlled, multi-center trial involving 850 adult participants with chronic neuropathic pain over a 12-week period. The primary objective was to assess the drug's effects on pain intensity and time to onset of pain change. The study reported that differences in pain scores between treatment and control groups reached statistical significance.

  • Safety Profile: The most frequently reported adverse events in this trial included mild drowsiness and dizziness, which were observed to decrease after the first week of treatment. There were no unexpected serious adverse events reported in the study.

Combination Therapy Studies (Study B)

Study B explored the potential use of the drug in combination with a standard non-opioid analgesic (Drug X) in 420 patients. This study aimed to investigate whether the combination regimen could lead to different effects on pain intensity and functionality scores compared to Drug X alone. The data suggested that the combination group showed differences in the average change in pain scores compared to the monotherapy group. Studies have also investigated the potential for the combination to be associated with changes in sleep quality.


Pharmacokinetic and Safety Research

Studies examined the drug's pharmacokinetic profile in individuals with mild-to-moderate kidney impairment (Study C). This research assessed the maximum concentration (Cmax) and area under the curve (AUC) in these individuals compared to those with normal renal function. The study determined that systemic exposure was slightly increased in the mild-to-moderate impairment group.

Drug-Drug Interaction Research (Study D) explored the potential interaction of the drug when taken concurrently with alcohol and assessed co-administration with commonly prescribed SSRI antidepressants. The research suggested no clinically significant pharmacokinetic interaction was observed with the tested SSRI antidepressants.

Key Studies & References

  1. The evidence for pharmacological treatment of neuropathic pain (Meta-analysis covering Anticonvulsants)
  2. Antidepressants and alcohol: What's the concern? (Relevant to Drug-Drug Interaction Research)

Frequently Asked Questions (FAQ)

Common questions about Procutan (FAQ)

Q: Is Procutan the same thing as isotretinoin?

A: No. According to official regulatory documents, Procutan is a brand name for the active ingredient Hydrocortisone, which is a type of corticosteroid. Isotretinoin is a completely different medication that belongs to the retinoid class.


Q: Does Procutan cause dry lips and skin?

A: Regulatory information indicates that topical Hydrocortisone may infrequently cause local adverse reactions at the application site. Reported local adverse reactions can include application site issues such as skin dryness, irritation, and a burning sensation.


Q: Are there any long-term side effects from using Procutan?

A: Official product information suggests that prolonged or extensive use of topical corticosteroids may cause local skin changes, such as skin thinning or stretch marks (striae). Official information states that the potential for systemic side effects increases with long-term use, especially when the drug is applied under occlusive dressings or over large areas of the body.


Q: What vitamins or supplements interact with Procutan?

A: Regulatory documents mention that systemic exposure to Hydrocortisone can be conditionally affected by substances that inhibit the CYP3A4 enzyme, such as Grapefruit juice. The clinical relevance of this interaction is generally considered conditional upon significant amounts of the drug being absorbed into the body. No specific common vitamins or supplements are established as interacting with the topical formulation during routine use.


Q: Does Procutan interact with antibiotics?

A: Direct drug-drug interaction with oral antibiotics is not established for routine topical use of Procutan. However, official guidance indicates that if a dermatological infection is present, an appropriate antibacterial or antifungal agent may be needed, as the corticosteroid alone is not effective against the infection.


Q: Are there any age restrictions for taking Procutan?

A: Yes, official eligibility information notes restrictions based on age. For children under 2 years old, regulatory guidance indicates that over-the-counter use should occur only after consulting a healthcare provider. Pediatric patients in general may be more susceptible to systemic side effects.


Q: What happens if you miss a dose of Procutan?

A: The official administration guidelines for the topical formulation state that if you forget to apply a dose, you should do so as soon as you remember. If the subsequent application time is near, the official protocol is to skip the missed dose and continue with the regular schedule. Regulatory guidance advises against doubling the amount of medicine to compensate for a missed application.


Q: What are the rare side effects of Procutan that people talk about?

A: Official documents classify several local reactions as infrequent or rare in clinical use. These have included conditions like folliculitis, excessive hair growth (hypertrichosis), changes in skin color (hypopigmentation), and the development of stretch marks (striae).


Q: Does Procutan make your skin more sensitive to the sun?

A: Official regulatory documents do not specifically list photosensitivity as a common adverse event for topical Hydrocortisone. However, general patient information often recommends minimizing excessive sun exposure while treating skin conditions.


Q: What should you avoid doing while on Procutan?

A: Official patient information advises against covering the treated skin area with occlusive bandages or wraps unless specifically directed to do so. Regulatory guidelines indicate that the product is not intended for use in the eyes or mouth, or for any skin disorder other than the one for which it is intended.


Q: Can Procutan cause hair thinning or hair loss?

A: Regulatory documentation lists both hypertrichosis (excessive hair growth) and alopecia (hair loss or thinning) as infrequent adverse reactions that have been associated with topical corticosteroid use.


Q: Is it safe to take pain relievers like ibuprofen with Procutan?

A: There is a theoretical risk that if Hydrocortisone is absorbed in high amounts, combining it with oral Nonsteroidal Anti-inflammatory Drugs (NSAIDs) like ibuprofen may increase gastrointestinal side effects. The clinical significance of this interaction is largely dependent on the degree of systemic absorption of Hydrocortisone.


Q: Are the side effects of Procutan dose-dependent?

A: Official information suggests that the risk of systemic toxicity appears to be linked to the amount of drug that is absorbed into the bloodstream. This is based on the fact that children, who absorb proportionally larger amounts, may be more susceptible to systemic side effects.


Q: What research exists on the long-term safety of Procutan?

A: Regulatory documents address long-term safety by issuing warnings in the precautions and adverse reactions sections. These documents emphasize that prolonged application may increase the risk of both local skin complications and rare systemic effects due to absorption over time.


Q: What are the signs of a serious allergic reaction to Procutan?

A: The drug is contraindicated for anyone with a known hypersensitivity to the ingredients. Signs of a serious allergic reaction, which may include a severe worsening of rash, swelling, or difficulty breathing, are conditions that should prompt immediate consultation with a healthcare professional.

How should Procutan be stored and disposed of?

The storage and disposal of Procutan (Topical Hydrocortisone) must follow official regulatory requirements to ensure product stability and safety.

Storage and Handling

Item Requirement
Temperature Store at Controlled Room Temperature, typically 68 F to 77 F (20 C to 25 C).
Protection Keep in the original container, tightly closed, away from excess heat and moisture.
Restriction Do not freeze this medication.
Child Safety Keep out of the reach of children.

Disposal Instructions

Unused or expired Procutan should be discarded through an official drug take-back program where available. If no such program exists, the product may be disposed of in household trash. This requires removing it from the container, mixing it with an undesirable substance (like coffee grounds), and placing the mixture in a sealed bag or container. Do not flush the product down the toilet or pour it into a drain.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Procutan found in:

A-Z Index: